Air Liquide Launches an Innovative Product for Anesthesia
Air Liquide was granted approval to market the pharmaceutical product xenon for anesthesia in Germany. This approval is a key step in the growth strategy of the pharmaceutical activity of the Air Liquide group which develops and provides innovative medications in gaseous form to medical teams and patients. This medical product will be launched in all those countries where Air Liquide Healthcare is present.
Xenon is a colourless and odourless rare gas. It is an extremely minute element of atmospheric air and its therapeutic effects were first noted in 1951. Thanks to its pharmaceutical properties, anesthetists consider xenon an ideal anesthetic with minimal side effects. Indeed numerous studies on patients in selected German and European clinics have been performed since 1998; they proved xenon is absorbed via the respiratory tract and does not affect the metabolism of a patient in any way. Furthermore, xenon has a very strong analgesic effect. Waking up and recovery of the patient following medical surgery can thus be achieved more easily and rapidly..
Other news from the department research and development
